ArticleCureus2026
Recurrent Infection-Triggered Immune Thrombocytopenia Flares in Medullary Sponge Kidney: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medullary sponge kidney (MSK) is a congenital collecting duct abnormality associated with nephrocalcinosis, recurrent nephrolithiasis, hematuria, urinary tract infections, and obstructive urological complications. Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia and bleeding risk. We report a case illustrating how these two chronic conditions can interact indirectly to create a recurrent management dilemma. A 45-year-old woman with bilateral MSK and chronic ITP controlled with weekly romiplostim had a baseline platelet count of approximately 120-130 × 10³/µL. Over several months, she experienced recurrent urological events, including obstructive nephropathy, extended-spectrum beta-lactamase (ESBL) urosepsis, pyelonephritis, ureteritis, and repeated ureteral stenting. During a March 2026 admission for right pyelonephritis with bilateral stents, her platelet count fell abruptly from approximately 120 × 10³/µL to 7 × 10³/µL, accompanied by gross hematuria, and improved after intravenous immunoglobulin and dexamethasone. She presented again in April 2026 with left flank pain, nausea, gross hematuria, leukocytosis, positive urinalysis, bilateral ureteral wall thickening, periureteral stranding, mild left hydronephrosis, and bilateral medullary calcifications consistent with MSK. Her platelet count had again declined to 27 × 10³/µL. Workup did not support thrombotic microangiopathy, disseminated intravascular coagulation, pseudothrombocytopenia, drug-induced thrombocytopenia, hemolysis, viral infection, or renal failure as alternative causes. She was treated with meropenem, fluconazole, hydration, analgesia, and intravenous immunoglobulin, while corticosteroids were deferred because of active infection and romiplostim was held. Platelets rose to 116-125 × 10³/µL within 48 hours, with resolution of hematuria and clinical improvement. This case emphasizes that recurrent MSK-related urinary infections may precipitate clinically significant ITP flares. Early platelet monitoring and coordinated hematology, infectious disease, and urology input are essential when infection control, bleeding risk, and procedural decisions overlap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.